8-K: Bolt Projects Reports Q3 2025 Revenue Up 7,300%, Boosts Profit Outlook

Bolt Projects Holdings, Inc. announced strong Q3 2025 financial results with revenue soaring 7,300% year-over-year and an increased gross profit outlook for fiscal 2025, alongside ongoing financing activities and Nasdaq listing compliance efforts.

Summary

• Q3 2025 revenue was $0.4 million, representing a 7,300% increase year-over-year from $5.0 thousand in Q3 2024.
• Gross margins improved to 16% in Q3 2025, up from 5% in Q2 2025 and 0% in Q3 2024.
• The full-year 2025 revenue guidance remains unchanged at $4.5 million, and 2026 guidance at $9.0 million.
• The 2025 gross profit outlook was increased from $0.5 million to over $1.0 million, with Q4 gross margin expected to exceed 40%.
• The company added two new customers, completed onboarding for a global beauty conglomerate, and deepened penetration with existing brands, including a new product launch (RAD-REMEDY) featuring b-silk targeted for Q4 2025.
• A collaboration with amika is advancing a first-of-its-kind Vegan Silk application in aerosol format.
• Operational scalability improved with further product cost reductions, and a new XL-Silk variant was scaled to manufacturing readiness in less than one month.
• Bolt earned a Silver-level rating from EcoVadis for its sustainability practices.
• The intellectual property portfolio expanded with three new patents, totaling 84 granted and 114 pending as of September 30, 2025.
• Financing activities included a $4.3 million private placement in August 2025, conversion of $1.7 million in vendor payables to equity in September 2025, and drawing $1.5 million from an equity line of credit in October 2025.
• A non-binding term sheet for up to $30 million in convertible debt financing with Murchinson Ltd. was entered into in October 2025, expected to close in December 2025.
• Net loss for Q3 2025 was $7.5 million, compared to net income of $6.4 million in Q3 2024, primarily due to remeasurement gains on warrant liabilities in the prior year.
• Adjusted EBITDA improved to ($2.5) million in Q3 2025 from ($2.8) million in Q3 2024.
• Cash and cash equivalents increased to $4.7 million as of September 30, 2025, from $1.0 million in the prior quarter.
• The company received a Nasdaq delisting notice on August 12, 2025, but was granted an extension to regain compliance on September 30, 2025.

Sentiment

Score: 7

Explanation: While the company faces significant challenges like a Nasdaq delisting notice and ongoing net losses, the substantial revenue growth, improved gross margins, increased gross profit outlook, strong customer traction, and successful capital raising activities indicate positive operational momentum and a clearer path towards sustainable profitability. The 'going concern' risk and Nasdaq compliance remain critical concerns.

Positives

• Q3 2025 revenue increased by 7,300% year-over-year to $0.4 million, demonstrating significant market traction.
• Gross margins improved substantially to 16% in Q3 2025, up from 0% in Q3 2024 and 5% in Q2 2025, indicating enhanced profitability.
• The 2025 gross profit outlook was doubled from $0.5 million to over $1.0 million, reflecting stronger expected financial performance.
• Q4 gross margin is expected to exceed 40%, with a long-term target of 60%, signaling continued operational efficiency gains.
• Strong customer acquisition with two new customers and deeper penetration with existing brands, including new product launches.
• Strategic collaboration with amika for a novel Vegan Silk application in aerosol format, expanding product categories.
• Achieved significant product cost improvements and demonstrated operational scalability by rapidly validating a new XL-Silk variant.
• Received a Silver-level rating from EcoVadis, recognizing commitment to responsible sourcing and sustainability.
• Strengthened intellectual property portfolio with three new patents, bringing the total to 84 granted and 114 pending.
• Successfully completed multiple financing activities, including a $4.3 million private placement and conversion of $1.7 million in vendor payables to equity.
• Secured a non-binding term sheet for up to $30 million in convertible debt financing, enhancing future liquidity.
• Cash and cash equivalents increased to $4.7 million as of September 30, 2025, from $1.0 million in the prior quarter, improving liquidity.
• Adjusted EBITDA improved to ($2.5) million in Q3 2025 from ($2.8) million in Q3 2024, showing a reduction in adjusted operating losses.

Negatives

• Reported a net loss of $7.5 million in Q3 2025, a significant decline from the net income of $6.4 million in Q3 2024.
• Received a notice of determination of delisting from Nasdaq on August 12, 2025, posing a risk to its public listing status.
• The company has a history of net losses and negative cash flows, raising concerns about long-term profitability.
• There is substantial doubt about the company's ability to continue as a going concern.
• Net loss per share was ($2.70) in Q3 2025, compared to $6.42 per share in Q3 2024.
• Total stockholders deficit increased to ($12,747) thousand as of September 30, 2025, from ($8,610) thousand as of December 31, 2024.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• The company has a history of net losses and negative cash flows.
• Ability to generate sufficient cash to service its debt is uncertain.
• The company's ability to meet Nasdaq's continued listing requirements and remain listed on a national stock exchange is not assured.
• There is no assurance that the company can execute its business plan, adequately control expenses, or raise additional capital on favorable terms, if at all.
• Dependence on sales of b-silk and xl-silk products from its Vegan Silk Technology Platform.
• Reliance on manufacturing partners in regions that could be impacted by U.S. trade policy, including renegotiating or terminating existing trade agreements and leveraging tariffs.
• Costs of and availability for its Vegan Silk Technology Platform products are out of the company's control.
• Reliance on a single manufacturing partner and manufacturing facility for the production of its Vegan Silk Technology Platform products.
• A limited number of customers, distributors, and collaboration partners account for a material portion of revenue, and the loss of major partners could harm operating results.
• Pricing and availability for the company's Vegan Silk Technology Platform products are subject to market forces.
• Market acceptance of products from consumer product companies is not guaranteed.
• The company's ability to adequately protect its patents and other intellectual property assets is crucial.
• Government regulations and private party actions relating to the marketing and advertising of cosmetic products could impact the business.
• There is no assurance that planned financing activities will be successful.
• There is no assurance that the company will ultimately regain compliance or be able to maintain compliance with all other applicable requirements for continued listing on the Nasdaq.

Future Outlook

The company maintains its revenue guidance of at least $4.5 million for 2025 and $9.0 million for 2026. It has increased its gross profit outlook for 2025 to over $1.0 million, implying more than 40% gross margins in Q4 2025, with a target of 60%. Management believes existing cash resources, combined with anticipated financing activities, will be sufficient to fund planned operations through mid-2026.

Management Comments

• Dan Widmaier, Chairman and CEO: "Demand for Vegan Silk continues to accelerate and drove another quarter of sequential gross margin expansion. Our focus remains balancing pricing discipline with market share gains as we scale toward sustainable profitability."
• Dan Widmaier, Chairman and CEO: "With stronger margins and increased efficiency, we're raising our gross profit outlook for fiscal 2025 from $0.5 million to over $1.0 million. This improvement implies more than 40% gross margins in the fourth quarter, well on our way to achieving our 60% target margin. Our focus remains on balancing price and margin to achieve sustainable profitability and readiness to scale through 2026."
• Cintia Nardi, President: "We are advancing a first-of-its-kind application of our Vegan Silk technology in the aerosol format, opening the door to new product categories and consumer experiences. This collaboration underscores the versatility of our platform beyond traditional formulations and represents a meaningful contributor to Bolts next phase of growth."
• Cintia Nardi, President: "The third quarter marked a turning point as commercial traction translated into measurable results. With accelerating reorders, new brand launches, and expanding use of our Vegan Silk platform, we're entering 2026 with strong visibility and a path to scale."
• David Breslauer, Chief Product & Technology Officer: "Bolt doesn't just ship an ingredient. We co-develop performance modules that meet a brand's specific brief and back them with evidence. By pairing our Vegan Silk platform with fast development, we're turning science into on-shelf results. That translates to customer reorders and improved margins as we scale."

Industry Context

Bolt Projects operates within the biomaterials sector, specifically targeting the beauty and personal care industry with its Vegan Silk Technology Platform. The increasing consumer demand for sustainable, vegan, and high-performance ingredients positions Bolt favorably. The company's ability to secure partnerships with both indie innovators and global conglomerates, and to develop novel applications like aerosol formats, demonstrates strong market acceptance and potential for disrupting traditional formulations. This aligns with broader industry trends emphasizing innovation, sustainability, and diversified product offerings.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• Remeasurement of related party private placement warrant liability of $0.1 million and ($12.7) million for the three months ended September 30, 2025 and September 30, 2024, respectively.
• Remeasurement of related party convertible notes of zero and ($1.8) million for the three months ended September 30, 2024 and September 30, 2025, respectively.

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth and improved profitability outlook, but also risk of dilution from equity raises and potential delisting from Nasdaq. The $30 million convertible debt facility could also impact future equity value.
• Employees: Continued operational scaling and R&D efforts suggest stability and potential growth opportunities.
• Customers: New product launches and deeper penetration with existing brands indicate strong value proposition and continued partnership.
• Creditors: The new convertible debt facility and existing debt obligations highlight the company's reliance on financing, with risks associated with its 'going concern' status.
• Suppliers: Strong operational quarter and focus on cost improvements suggest stable relationships, but reliance on a single manufacturing partner poses a risk.

Next Steps

• Launch of Dr. Nancy Franklin's second brand, RAD-REMEDY, featuring b-silk, targeted for Q4 2025.
• Market introduction of the first-of-its-kind Vegan Silk application in aerosol format with amika.
• Closing of the $30 million convertible debt facility with Murchinson Ltd. in December 2025, subject to shareholder approval.
• Continued efforts to regain and maintain compliance with Nasdaq listing standards.
• Execution of anticipated financing activities to fund operations through mid-2026.

Key Dates

Recommendation

The company demonstrates significant operational improvements with substantial revenue growth, improving gross margins, and a raised gross profit outlook. Strong customer traction and strategic partnerships validate its product platform. However, the ongoing net losses, the 'going concern' warning, and the Nasdaq delisting notice introduce considerable risk. While recent financing activities provide liquidity, the long-term financial stability and ability to meet listing requirements remain uncertain. An investor should hold to monitor the successful execution of the financing plans, continued operational improvements, and resolution of the Nasdaq compliance issue before considering further investment.

Keywords

biomaterials, vegan silk, beauty industry, personal care, financial results, Q3 2025, Nasdaq listing, capital raise, gross margin, revenue growth, intellectual property, sustainability, BSLK, Bolt Projects Holdings